Investor Presentation

Date:17July2026 Ref.No.:TCPCL/SEC/2026-27/00022 TheGeneralManager, TheManager, Corporaterelationshipdepartment, Listing department, BSELimited NationalStockExchange ofIndiaLimited PhirozeJeejeebhoyTowers, ExchangePlaza,C-1,Block-G, DalalStreet, Fort, Bandra-KurlaComplex,Bandra(E), Mumbai-400001 Mumbai-400051 ScripCode:543321 ScripSymbol:TATVA Subject:Investor Presentation DearSir/Madam, Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed Investor Presentation for the quarter ended 30June2026. The above information shall be made available on the website of the Company at www.tatvachintan.com. Thisisfor yourinformationandrecords. Thankingyou, Yoursfaithfully, ForTatva ChintanPharma ChemLimited Ishwar Nayi CompanySecretaryandCompliance Officer M.No.:A37444 Encl.:Asabove Investor Presentation Tatva Chintan Pharma Chem Limited (TCPCL) Q1FY27 17 July 2026 Contents 01 02 03 04 Quarterly & twelve-month TATVA CHINTAN at Glance Product Categories Leading Sustainable Financial Performance practices coupled with cutting edge technology 05 06 07 08 Expansive international Why TATVA CHINTAN Industry Outlook Our Business presence with Marquee clientele Consolidated Financial Performance Q1FY27: Financial Result highlights FY26 HIGHLIGHTS Tatva Chintan Pharma Chem Limited 4 728,3 950,5 Revenue from Operations1(In ₹ Mn) FY25 FY26 243 239 EBIDTA (Excl. Other Income) & EBIDTA Margin1(In ₹ Mn, %) 1,000 21.0% 18.4% 900 19.0% 800 17.0% 700 15.0% 600 13.0% 8.9% 11.0% 400 9.0%172% 300 200 7.0% YoY 100 5.0% - 3.0% FY25 FY26 EBITDA (Excl. EBITDA Margin Q1FY27 HIGHLIGHTS PAT & PAT Margin1(In ₹ Mn, %) 450 10.0% 8.3% 8.0% 350 300 6.0% 4.0% 636% 150 1.5% 2.0% 100 YoY 0.0% 0 -2.0% FY25 FY26 PAT PAT Margin Notes: (1) Numbers have been rounded off. 961,1 143,1 176,1 Revenue from Operations1(In ₹ Mn) Q1FY26 Q4FY26 Q1FY27 371 182 323 EBIDTA (Excl. Other Income) & EBIDTA Margin1(In ₹ Mn, %) 350 25.0% 21.0% 19.0% 300 20.0% 250 15.0% 200 15.0% 150 10.0% 86% 100 5.0% YoY 50 - 0.0% Q1FY26 Q4FY26 Q1FY27 EBITDA (Excl. Other Income) PAT & PAT Margin1(In ₹ Mn, %) 9.6% 180 5.7% 7.7% 11.0% 9.0% 140 7.0% 120 5.0% 100 80 3.0%140% 60 1.0% YoY 40 103 -1.0% 160 20 -3.0% - -5.0% Q1FY26 Q4FY26 Q1FY27 PAT PAT Margin 48.2 14.4 38.6 EPS (In ₹) 8.00 7.00 6.00 5.00 4.00 3.00 2.00 1.00 Q1FY26 Q4FY26 Q1FY27 44.2 89.71 EPS (In ₹) 20.00 18.00 16.00 14.00 12.00 10.00 8.00 6.00 4.00 2.00 0.00 FY25 FY26 Q1FY27: Consolidated Numbers Particulars (₹ Mn) Q1FY27 Q1FY26 YoY (%) Q4FY26 QoQ (%) FY26 FY25 YoY (%) Revenue from Operation 1,671 1,169 43% 1,341 25% 5,059 3,827 32% Total Income 1,698 1,180 44% 1,338 27% 5,094 3,850 32% EBITDA (Excl. Other Income) 323 173 86% 281 15% 932 342 172% EBITDA Margin 19% 15% 30% 21% -8% 18% 9% 106% Profit Before Tax 211 91 132% 166 27% 570 76 652% Profit After Tax 160 67 140% 103 55% 421 57 636% PAT Margin 10% 6% 68% 8% 24% 8% 1% 457% Tatva Chintan Pharma Chem Limited 5 Q1 FY27 & FY26: Operational highlights OPERATING REVENUE SPLIT (IN %) Others Others 1% PTC 26% PASC 23% PASC Q1FY27 PTC FY26 PTC SDA SDA ESS 3% ESS 4% SDA SDA 34% PASC 41% PASC Others Others Tatva Chintan Pharma Chem Limited 6 Consolidated Financial Highlights REVENUE FROM OPERATIONS1 (IN ₹ MN) Tatva Chintan Pharma Chem Limited 7 633,4 632,4 539,3 728,3 950,5 75 23 FY22 FY23 FY24 FY25 FY26 Revenue from Operations Other Income 959 554 403 75 PROFITABILITY1(IN ₹ MN) EBITDA (Excluding Other Income) & EBITDA Margin PAT & PAT Margin 22% 11% 8% 1% 8% FY22 FY23 FY24 FY25 FY26 PAT PAT Margin Notes: (1) Numbers have been rounded off 280,1 606 286 25% 14% 17% 9% FY22 FY23 FY24 FY25 FY26 EBITDA EBITDA Margin %3.02 %8.8 %1.4 %8.0 %2.7 RoE (IN %) FY22 FY23 FY24 FY25 FY26 52.0 33.0 20.0 50.0 51.0 Debt to Equity (x) FY22 FY23 FY24 FY25 FY26 20.1 75.2 91.0 00.1 92.1 Debt to EBIDTA (x) FY22 FY23 FY24 FY25 FY26 Consolidated Statement of Profit & Loss Particulars (₹ Mn) 31-Mar-20 31-Mar-21 31-Mar-22 31-Mar-23 31-Mar-24 31-Mar-25 31-Mar-26 Audited Audited Audited Audited Audited Audited Audited Income Revenue from operations 2,632.39 3,003.59 4,336.47 4,236.12 3,935.04 3,827.14 5,058.58 Other income 13.83 52.00 90.17 57.44 75.09 23.15 35.49 Total Income 2,646.22 3,055.59 4,426.64 4,293.56 4,010.13 3,850.29 5,094.07 Expenses Cost of goods sold 1,327.67 1,520.05 1,946.39 2,261.01 1,741.82 1,989.41 2,245.39 Employee benefit expenses 205.29 238.02 308.18 412.09 547.61 529.16 629.31 Finance costs 39.45 42.07 49.51 84.04 65.32 12.90 28.51 Depreciation and amortization expense 47.93 67.33 81.80 95.55 256.05 276.59 368.47 Other expenses 549.91 581.16 999.55 957.21 963.65 966.44 1,252.30 Total expenses 2,170.25 2,448.63 3,385.43 3,809.90 3,574.45 3,774.50 4,523.98 Profit before exceptional items and tax 475.97 606.96 1,041.21 483.66 435.68 75.79 570.09 Exceptional items - - - 35.87 - - - Profit before tax (PBT) 475.97 606.96 1,041.21 447.79 435.68 75.79 570.09 Total tax 98.08 84.34 82.47 (7.08) 132.14 18.66 149.55 Profit after tax (PAT) 377.89 522.62 958.74 454.87 303.54 57.13 420.54 PAT % 14% 17% 22% 11% 8% 1% 8% Earnings per share (EPS) ₹ 18.81 26.02 44.59 20.52 13.26 2.44 17.98 EBIDTA ₹ 549.52 664.36 1,082.35 605.81 681.96 342.13 931.58 EBIDTA % 21% 22% 25% 14% 17% 9% 18% ETR 21% 14% 8% -2% 30% 25% 26% Tatva Chintan Pharma Chem Limited 8 Consolidated Statement of Balance Sheet Particulars (₹ Mn) 31-Mar-20 31-Mar-21 31-Mar-22 31-Mar-23 31-Mar-24 31-Mar-25 31-Mar-26 Audited Audited Audited Audited Audited Audited Audited Assets Fixed Assets 1,110.60 1,203.51 1,592.96 1,957.71 4,265.35 5,255.52 6,041.47 Capital work-in-progress 48.92 98.11 514.91 2,307.44 729.27 215.35 233.48 Intangible assets (Including CWIP) 1.20 0.95 3.17 4.76 39.61 58.99 68.26 Other non-current assets 1.67 2.96 113.12 157.54 173.89 180.18 198.61 Total non-current assets 1,162.39 1,305.53 2,224.16 4,427.45 5,208.12 5,710.04 6,541.82 Inventory 635.55 720.19 1,699.58 1,624.98 1,527.66 1,339.54 1,960.74 Trade Receivable 495.71 907.43 565.98 844.03 698.52 825.27 1,190.31 Cash and cash equivalents including bank balance 108.29 53.42 1,769.86 447.61 353.04 140.96 87.91 Other current assets 87.44 161.46 320.97 218.93 399.84 338.15 288.08 Total current assets 1,326.99 1,842.50 4,356.39 3,135.55 2,979.06 2,643.92 3,527.04 Total assets 2,489.38 3,148.03 6,580.55 7,563.00 8,187.18 8,353.96 10,068.86 Equity and liabilities Equity share capital 80.35 200.88 221.65 221.65 233.92 233.92 233.92 Other equity 1,096.59 1,458.76 4,509.24 4,926.26 7,136.90 7,154.32 7,583.67 Tangible net worth 1,176.94 1,659.64 4,730.89 5,147.91 7,370.82 7,388.24 7,817.59 Liabilities Non-current liabilities (i) Long-term borrowings 387.09 267.63 131.11 42.30 6.39 - 50.10 (ii) Other non-current liabilities 48.85 40.61 6.59 11.45 13.34 13.98 37.90 Total non-current liabilities 435.94 308.24 137.70 53.75 19.73 13.98 88.00 Current liabilities (i) Short-term Borrowings including current maturities 519.80 634.85 1,068.27 1,660.27 136.62 363.88 1,153.63 (ii) Trade payables 316.13 474.77 445.13 321.88 450.31 326.89 582.46 (iii) Other liabilities 40.57 70.53 198.56 379.19 209.99 260.97 427.18 Total current liabilities 876.50 1,180.15 1,711.96 2,361.34 796.63 951.74 2,163.27 Total equity and liabilities 2,489.38 3,148.03 6,580.55 7,563.00 8,187.18 8,353.96 10,068.86 Tatva Chintan Pharma Chem Limited 9 TATVA CHINTAN at Glance TATVA CHINTAN at Glance INTEGRATED SPECIALTY CHEMICAL COMPANY, PRESENT ACROSS THE VALUE CHAIN • Established by first generation entrepreneur engineers in Manufacturing Products Revenue Split – FY26 1996 • Plants located at Ankleshwar and Dahej SEZ, Gujarat with an Phase Transfer existing combined installed reactor capacity of 791KL & 39 Catalyst (PTC) Assembly Lines as on 31 March 2026 • Sate of the Art R&D Unit recognized by DSIR at Vadodara, FY26 Gujarat Structure Directing • Pioneers in processes such as conventional synthesis, Agents (SDA) electrolysis and developing continuous flow chemistry which is a gre [Showing first 8,000 characters — download PDF for full document]